Plain English Summary
Background and study aims
Lower Urinary Tract Symptoms (LUTS) as hesitating, frequency and nocturia are common problems under men above 50 years. LUTS is not caused by the dysfunction the prostate only, but as the disruption of different processes in the bladder, prostate pelvic floor and urethra. Patients are now treated by the guidelines of the Dutch GP's. In general practice, there is a lack of diagnostic tools. Uroflowmetry and ultrasound bladder scanning are important diagnostic tools in LUTS management assessed by the urologist
Who can participate?
Male patients aged 50 and older, who were consulting their GP with lower urinary tract symptoms for the first time.
What does the study involve?
In our study we made two groups; both groups received primary-care treatment involving with or without uroflowmetry and post-void ultrasound bladder scanning. A year after inclusion we counted the referrals to the urologists in both groups. Thereby we asked the participants if they had more or fewer complaints after a year, if they were satisfied with the treatment and if they used medication.
What are the possible benefits and risks of participating?
There were no short time benefits or possibly harms for the participants.
Where is the study run from?
Radboud University Nijmegen Medical Centre (Netherlands)
When is the study starting and how long is it expected to run for?
October 2010 to March 2018
Who is funding the study?
Agis Health insurance, (now Zilveren Kruis Achmea)
Who is the main contact?
H.A. Lammers, firstname.lastname@example.org
Mr H.A. Lammers
The usefulness of uroflowmetry and ultrasound bladder scanning as diagnostic tools in primary care for new male patients with lower urinary tract symptoms; a cluster randomized controlled trial
Implementing uroflowmetry and post void ultrasound bladder scanning in primary care for men with LUTS will reduce the number of referrals to urologists.
Approved 26/10/2010, Medical ethics review committee Arnhem-Nijmegen (Huispost 578, Postbus, 9101, UMC St Radboud Centraal, route 578, Geert Grooteplein 10; +31 24 3613154; cmo@iwkv,ucmn.nl), ref: 2010/098
Cluster randomized controlled trial
Primary study design
Secondary study design
Randomised controlled trial
Patient information sheet
No participant information sheet available
Lower urinary tract symptoms
A cluster randomized controlled trial (RCT) was conducted in general practices in the Netherlands with a total patient population of 24,000. Randomization took place at GP level instead of at patient level to minimize the effects of contamination. A total of 11 GPs were included. Randomization took place in a manual way by the head investigator under control of an independent colleague.
After informed consent, the patients in the intervention group received the usual general practice care with two additional diagnostics tests, namely uroflowmetry and post-void ultrasound bladder scanning, conducted by a trained research assistant under standardized conditions, to assess peak flow and post-void residual volume. The control group received the same care without the two investigations.
The number of referrals to a urologist within 3 and 12 months was assessed with a patient questionnaire.
Primary outcome measure
Number of patients referred to urologists within 3 and within 12 months after first consultation measured using patient records
Secondary outcome measures
1. Severity of the symptoms measured using IPSS and IPSS-QOL at baseline and one year of follow up
2. Patient satisfaction measured using a Likert scale of 1 to 5 (very dissatisfied to very satisfied) after one year of follow up
3. Urologic medication use (alpha-blocker or 5ARI) measured using patient questionnaire after one year of follow up
Overall trial start date
Overall trial end date
Reason abandoned (if study stopped)
Participant inclusion criteria
Patients aged 50 and older, who were consulting their GP with LUTS for the first time. LUTS were defined as ‘micturition problems not evidently explained by a specific condition’, in accordance with the definition found in the practice guideline of the Dutch College of General Practitioners
Target number of participants
Participant exclusion criteria
1. Medication usage (alpha-blockers, 5-alpha-reductase inhibitors or anticholinergics)
2. Previous visits to a urologist because of LUTS
3. Diagnosed or suspected prostate cancer; and a diagnosed urinary tract infection, haematuria or other urologic pathology
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
Radboud university medical center
Dept. of Primary and Community Care Geert Grooteplein 21
Radboud University Nijmegen Medical Centre
Dept. of Primary and Community Care
Geert Grooteplein 21
Agis Health insurance, (now Zilveren Kruis Achmea)
Funding Body Type
Funding Body Subtype
Results and Publications
Publication and dissemination plan
Planned publication in a high impact peer-reviewed journal.
IPD sharing statement:
The datasets generated during and/or analysed during the current study are/will be available upon request from H.A. Lammers, email: email@example.com. The data includes measurements of all baseline characteristics of the participant: age, results of uroflowmetry and bladder scan, IPSS questionnaire at baseline and after 12 months, satisfaction and medication questionnaires after 12 years of follow up. The data are available from 01/01/2020 until 01/01/2025. Also available are the informed consent and statistical analyses on every reasonable request. ). This study was conducted in accordance with the Declaration of Helsinki.
Intention to publish date
Participant level data
Available on request
Basic results (scientific)